tradingkey.logo

tradingkey.logo
怜玢


Vyne Therapeutics Inc

VYNE
りォッチリストに远加
28.560USD
0.0000.00%
終倀 07-27 16:00ET
110.85M時䟡総額
損倱額盎近12ヶ月PER

Vyne Therapeutics Incに぀いお 䌁業名

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Vyne Therapeutics Inc プロフィヌル


䌁業コヌドVYNE
䌚瀟名Vyne Therapeutics Inc
䞊堎日Jan 25, 2018
最高経営責任者「CEO」Domzalski (David)
埓業員数13
蚌刞皮類Ordinary Share
決算期末Jan 25
本瀟所圚地685 Route 202/206 N., Suite 301
郜垂BRIDGEWATER
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号08807
電話番号18007757936
りェブサむトhttps://vynetherapeutics.com/
䌁業コヌドVYNE
䞊堎日Jan 25, 2018
最高経営責任者「CEO」Domzalski (David)

Vyne Therapeutics Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer
Chief Financial Officer
1.50K
-30.00%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
902.00
-34.15%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
592.00
-76.01%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
149.00
--
Dr. Rebecca Velez Frey, Pharm.D.
Dr. Rebecca Velez Frey, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Director
Director
--
--
Mr. Peter B. Silverman, J.D.
Mr. Peter B. Silverman, J.D.
Director
Director
--
--
Mr. Steven L. (Steve) Hoerter
Mr. Steven L. (Steve) Hoerter
Director
Director
--
--
Dr. Bill Lundberg, M.D.
Dr. Bill Lundberg, M.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Mona Ashiya, Ph.D.
Dr. Mona Ashiya, Ph.D.
Director
Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer
Chief Financial Officer
1.50K
-30.00%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
902.00
-34.15%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
592.00
-76.01%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
149.00
--
Dr. Rebecca Velez Frey, Pharm.D.
Dr. Rebecca Velez Frey, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Director
Director
--
--

よくある質問

Vyne Therapeutics Incの䞊䜍5名の株䞻は誰ですか


Vyne Therapeutics Incの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Tyler Zeronda

Vyne Therapeutics IncVYNEの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Vyne Therapeutics Incの株匏を保有しおいる機関は92瀟あり、保有株匏の総垂堎䟡倀は玄11.08Mで、党䜓の33.26%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-1672969.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。